alpha 1 antitrypsin

alpha 1 antitrypsin

A 54 kD glycoprotein that inhibits proteolytic enzymes (proteases),trypsin, chymotrypsin, elastases in lysosomes, plasmin, thrombin, collagenase, and others. Serum A1AT increases nonspecifically during inflammation and is a so-called acute phase reactant.
Elevated A1AT Inflammation, liver injury, increased oestrogen, pregnancy, malignancy, corticosteroid therapy.
Reduced A1AT Heterozygous A1AT deficiency, emphysema, prematurity, protein-losing disorders.
Ref range 2–4 g/L.
References in periodicals archive ?
Protein replacement therapy, involving weekly infusions of plasma-derived alpha 1 antitrypsin is approved but is only reimbursed in the United States and some European countries.
Contract notice: Provision of the drug alpha 1 antitrypsin (doe) for all osakidetza service organizations.
Active substance: Alpha 1 antitrypsin (doe) amount of active ingredient: 1 gr pharmaceutical form: Vial packaging conditions: Unit dose maximum price: 229 eur / vial of 1 gr (taxes not included).
Determination of alpha 1 antitrypsin phenotypes in plasma using isoelectric focusing on this agarose gel.
Alpha 1 proteinase inhibitor is intended for therapy of congenital alpha 1 antitrypsin deficiency, which leads to emphysema.
Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for pi type Z.